
  
    
      
        
        For_IN people_NNS who_WP received_VBD their_PRP$ introduction_NN to_TO cancer_NN genetics_NNS in_IN college_NN in_IN the_DT first_JJ
        half_NN of_IN the_DT 1990_CD s_VBZ ,_, everything_NN looked_VBD simple_JJ and_CC straightforward_JJ ._. It_PRP was_VBD the_DT stuff_NN you_PRP could_MD
        explain_VB to_TO sincerely_RB interested_JJ relatives_NNS who_WP wanted_VBD to_TO know_VB what_WP you_PRP were_VBD spending_VBG your_PRP$
        time_NN on_IN ._. There_EX were_VBD oncogenes_NNS and_CC there_EX were_VBD tumour_NN suppressor_NN genes_NNS ._. Oncogenes_NNS were_VBD
        overactive_JJ genes_NNS and_CC proteins_NNS that_WDT somehow_RB caused_VBN cancer_NN because_IN they_PRP were_VBD overactive_JJ ;_:
        therefore_RB ,_, they_PRP were_VBD dominant_JJ ._. Tumour_NNP suppressor_NN genes_NNS were_VBD genes_NNS that_WDT would_MD normally_RB
        prevent_VB a_DT tumour_NN from_IN happening_VBG and_CC that_WDT needed_VBD to_TO be_VB inactivated_JJ for_IN a_DT tumour_NN to_TO start_VB to_TO
        form_VB ;_: both_DT copies_NNS of_IN a_DT tumour_NN suppressor_NN gene_NN had_VBD to_TO be_VB inactivated_JJ ,_, and_CC the_DT mutation_NN was_VBD
        recessive_JJ ._. If_IN inactivation_NN of_IN these_DT genes_NNS is_VBZ a_DT random_JJ process_NN ,_, it_PRP was_VBD understandable_JJ that_IN
        people_NNS who_WP inherit_VBP an_DT inactivated_JJ copy_NN of_IN a_DT tumour_NN suppressor_NN gene_NN had_VBD a_DT higher_JJR risk_NN of_IN
        developing_VBG the_DT associated_VBN form_NN (_( s_VBZ )_) of_IN cancer_NN than_IN people_NNS born_VBN with_IN two_CD normal_JJ copies_NNS ,_, as_IN
        postulated_JJ in_IN Alfred_NNP Knudson_NNP 's_POS (_( 1971_CD )_) two-hit_JJ model_NN ._. And_CC ,_, indeed_RB ,_, it_PRP was_VBD shown_VBN that_IN in_IN the_DT
        tumours_NNS in_IN these_DT predisposed_JJ patients_NNS ,_, the_DT remaining_VBG wild-type_JJ copy_NN of_IN the_DT tumour_NN
        suppressor_NN gene_NN was_VBD lost_VBN ,_, a_DT process_NN referred_VBD to_TO as_IN loss_NN of_IN heterozygosity_NN ._.
        For_IN me_PRP ,_, in_IN 1998_CD things_NNS started_VBD to_TO change_VB ._. Venkatachalam_NNP et_CC al_NN ._. (_( 1998_CD )_) published_VBD a_DT paper_NN
        in_IN the_DT 
        EMBO_NNP Journal_NNP describing_VBG a_DT detailed_VBN study_NN of_IN tumours_NNS in_IN mice_NNS lacking_VBG one_CD
        copy_NN of_IN the_DT p_NN 53_CD tumour_NN suppressor_NN gene_NN (_(
        Trp_NNP 53_CD )_) ._. This_DT gene_NN is_VBZ known_VBN to_TO be_VB the_DT most_RBS mutated_VBN gene_NN in_IN human_JJ cancer_NN
        and_CC its_PRP$ function_NN to_TO be_VB central_JJ to_TO many_JJ processes_NNS that_WDT are_VBP involved_VBN in_IN the_DT cellular_JJ
        prevention_NN of_IN cancer_NN ._. Mice_NNS lacking_VBG both_DT copies_NNS of_IN this_DT gene_NN are_VBP for_IN the_DT most_JJS part_NN viable_JJ ,_,
        but_CC succumb_NN to_TO cancer_NN (_( mainly_RB thymic_JJ lymphomas_NNS )_) at_IN three_CD to_TO five_CD months_NNS of_IN age_NN (_( Donehower_NNP
        et_CC al_NN ._. 1992_CD )_) ._. Mice_NNS born_VBN with_IN one_CD copy_NN of_IN the_DT 
        Trp_NNP 53_CD gene_NN start_NN to_TO develop_VB cancer_NN at_IN around_IN nine_CD months_NNS ,_, and_CC incidence_NN
        increases_NNS with_IN age_NN ._.
        In_IN their_PRP$ study_NN ,_, Venkatachalam_NNP and_CC colleagues_NNS analysed_JJ an_DT impressive_JJ group_NN of_IN 217_CD 
        Trp_NNP 53_CD
        +_NN /_NN −_NN mice_NNS of_IN controlled_VBN genetic_JJ background_NN and_CC followed_VBD the_DT fate_NN of_IN the_DT 
        Trp_NNP 53_CD wild-type_JJ allele_NN in_IN the_DT tumours_NNS ._. According_VBG to_TO the_DT two-hit_JJ model_NN ,_, it_PRP
        was_VBD expected_VBN that_IN in_IN these_DT tumours_NNS this_DT copy_NN would_MD have_VB been_VBN lost_VBN or_CC inactivated_JJ ._. However_RB ,_,
        this_DT turned_VBD out_IN not_RB to_TO be_VB the_DT case_NN ._. Half_NN of_IN the_DT tumours_NNS from_IN mice_NNS younger_JJR than_IN 18_CD months_NNS
        were_VBD found_VBN to_TO have_VB retained_VBN the_DT wild-type_JJ copy_NN of_IN 
        Trp_NNP 53_CD ,_, a_DT number_NN that_WDT increased_VBD to_TO 85_CD %_NN in_IN mice_NNS older_JJR than_IN 18_CD months_NNS ._. In_IN
        two_CD tumours_NNS ,_, the_DT researchers_NNS sequenced_JJ the_DT complete_JJ coding_VBG region_NN of_IN the_DT remaining_VBG
        wild-type_JJ allele_NN and_CC showed_VBD it_PRP was_VBD structurally_RB intact_JJ ._. To_TO exclude_VB the_DT possibility_NN of_IN
        downregulation_NN or_CC inactivation_NN at_IN the_DT level_NN of_IN protein_NN expression_NN ,_, they_PRP irradiated_JJ
        tumour-bearing_JJ mice_NNS prior_RB to_TO sacrifice_VB ,_, a_DT treatment_NN known_VBN to_TO increase_VB p_NN 53_CD protein_NN levels_NNS
        via_IN posttranslational_NN mechanisms_NNS ._. Their_PRP$ data_NNS showed_VBD the_DT retained_VBD wild-type_JJ allele_NN in_IN these_DT
        tumours_NNS was_VBD expressed_VBN normally_RB and_CC suggested_VBD it_PRP had_VBD a_DT normal_JJ wild-type_JJ conformation_NN ._.
        Next_JJ ,_, the_DT authors_NNS did_VBD a_DT rigorous_JJ test_NN of_IN different_JJ functions_NNS of_IN the_DT p_NN 53_CD protein_NN ._. They_PRP
        first_RB tested_VBN whether_IN the_DT tumours_NNS showed_VBD amplification_NN of_IN Mdm_NNP 2_CD ._. This_DT protein_NN ,_, whose_WP$
        expression_NN is_VBZ regulated_VBN by_IN p_NN 53_CD ,_, stimulates_NNS breakdown_NN of_IN p_NN 53_CD ,_, thereby_RB forming_VBG a_DT negative_JJ
        feedback_NN mechanism_NN that_WDT keeps_VBZ p_NN 53_CD levels_NNS low_JJ ._. Some_DT tumours_NNS therefore_RB amplify_VB the_DT 
        Mdm_NNP 2_CD gene_NN as_IN a_DT means_NN of_IN inactivating_VBG p_NN 53_CD ._. However_RB ,_, this_DT was_VBD not_RB found_VBN in_IN
        the_DT tumours_NNS from_IN the_DT 
        Trp_NNP 53_CD
        +_NN /_NN −_NN mice_NNS ._. Subsequently_RB ,_, the_DT researchers_NNS tested_VBN to_TO what_WP extent_NN the_DT
        retained_VBD 
        Trp_NNP 53_CD copy_NN behaved_VBD normally_RB ._. Irradiation_NNP of_IN many_JJ tissues_NNS leads_VBZ to_TO
        p_NN 53_CD -_: dependent_JJ apoptosis_NNS ,_, and_CC ,_, indeed_RB ,_, in_IN tumours_NNS that_WDT had_VBD retained_VBN the_DT wild-type_JJ allele_NN ,_,
        irradiation_NN did_VBD lead_VBN to_TO an_DT increase_NN in_IN apoptosis_NNS ,_, whereas_IN in_IN tumours_NNS that_WDT had_VBD lost_VBN the_DT
        wild-type_JJ allele_NN ,_, it_PRP did_VBD not_RB ._.
        The_DT p_NN 53_CD protein_NN is_VBZ known_VBN to_TO function_VB as_IN a_DT transcriptional_NN regulator_NN by_IN either_DT up-_NN or_CC
        down_RB regulating_VBG target_NN genes_NNS in_IN response_NN to_TO different_JJ forms_NNS of_IN cellular_JJ stress_NN ,_, including_VBG
        irradiation-induced_JJ DNA_NNP damage_NN ._. The_DT authors_NNS studied_VBD the_DT expression_NN of_IN two_CD p_NN 53_CD -_: upregulated_JJ
        genes_NNS (_(
        Cdkn_NNP 1_CD a_DT ,_, which_WDT encodes_NNS p_NN 21_CD ,_, and_CC 
        Mdm_NNP 2_LS )_) and_CC one_CD downregulated_JJ gene_NN (_(
        Pcna_NNP )_) in_IN p_NN 53_CD -_: positive_JJ tumours_NNS after_IN irradiation_NN and_CC showed_VBD responses_NNS
        indicative_JJ of_IN normal_JJ p_NN 53_CD function_NN ._. Furthermore_RB ,_, it_PRP was_VBD shown_VBN that_IN the_DT p_NN 53_CD protein_NN from_IN the_DT
        tumours_NNS was_VBD able_JJ to_TO bind_NN to_TO a_DT p_NN 53_CD -_: binding_JJ DNA_NNP sequence_NN in_IN an_DT in_IN vitro_NN setting_NN ._. Finally_RB ,_,
        since_IN it_PRP is_VBZ known_VBN that_DT p_NN 53_CD absence_NN in_IN tumours_NNS is_VBZ correlated_JJ with_IN chromosomal_NN instability_NN ,_,
        Venkatachalam_NNP et_CC al_NN ._. (_( 1998_CD )_) used_VBN comparative_JJ genome_NN hybridisation_NN to_TO compare_VB this_DT feature_NN
        between_IN p_NN 53_CD -_: negative_NN and_CC p_NN 53_CD -_: positive_JJ tumours_NNS and_CC found_VBD a_DT 5_CD -_: fold_VB greater_JJR stability_NN in_IN the_DT
        latter_NN ._.
        In_IN short_JJ ,_, this_DT paper_NN clearly_RB showed_VBD that_IN ,_, at_IN least_JJS in_IN mice_NNS ,_, in_IN many_JJ 
        Trp_NNP 53_CD
        +_NN /_NN −_NN tumours_NNS the_DT wild-type_JJ allele_NN of_IN 
        Trp_NNP 53_CD is_VBZ not_RB only_RB retained_VBD ,_, but_CC also_RB appears_VBZ to_TO function_VB normally_RB ._. This_DT
        strongly_RB suggested_VBN that_IN a_DT decrease_NN of_IN dosage_NN in_IN p_NN 53_CD is_VBZ already_RB sufficient_JJ for_IN
        tumourigenesis_NNS ,_, a_DT phenomenon_NN referred_VBD to_TO as_IN haploinsufficiency_NN ._. Shortly_RB before_RB ,_, the_DT group_NN
        of_IN Moshe_NNP Oren_NNP (_( Gottlieb_NNP et_CC al_NN ._. 1997_CD )_) had_VBD shown_VBN that_IN a_DT 
        Trp_NNP 53_CD
        +_NN /_NN −_NN background_NN leads_VBZ to_TO a_DT greater_JJR than_IN 50_CD %_NN reduction_NN in_IN p_NN 53_CD activity_NN
        using_VBG a_DT p_NN 53_CD -_: responsive_JJ 
        lacZ_NN reporter_NN gene_NN in_IN transgenic_JJ mice_NNS ._. Venkatachalam_NNP and_CC colleagues_NNS
        suggested_VBD the_DT strong_JJ concentration_NN dependence_NN of_IN p_NN 53_CD function_NN could_MD be_VB explained_VBN by_IN the_DT
        fact_NN that_DT p_NN 53_CD functions_NNS as_IN a_DT tetramer_NN ._. A_DT 50_CD %_NN decrease_NN in_IN p_NN 53_CD monomers_NNS can_MD easily_RB be_VB
        imagined_VBN to_TO result_VB in_IN a_DT greater_JJR than_IN 50_CD %_NN decrease_NN in_IN functional_JJ tetramers_NNS ,_, which_WDT in_IN turn_NN
        increases_NNS the_DT chances_NNS of_IN these_DT cells_NNS becoming_VBG cancerous_JJ ._.
        This_DT paper_NN by_IN Venkatachalam_NNP et_CC al_NN ._. (_( 1998_CD )_) made_VBN me_PRP realise_NN how_WRB important_JJ it_PRP is_VBZ to_TO remain_VB
        critical_JJ ,_, even_RB of_IN long-established_JJ theories_NNS and_CC models_NNS ._. Since_IN then_RB ,_, haploinsufficient_NN
        mechanisms_NNS have_VBP been_VBN described_VBN in_IN more_JJR tumour_NN suppressor_NN genes_NNS in_IN humans_NNS and_CC mice_NNS (_( reviewed_VBN
        in_IN Fodde_NNP and_CC Smits_NNP 2002_CD )_) ._. For_IN instance_NN ,_, in_IN a_DT recent_JJ paper_NN in_IN 
        PLoS_NNP Biology_NNP ,_, Trotman_NNP et_CC al_NN ._. (_( 2003_CD )_) used_VBN mouse_NN models_NNS to_TO describe_VB how_WRB
        the_DT dosage_NN of_IN the_DT 
        Pten_NNP tumour_NN suppressor_NN gene_NN influences_VBZ the_DT occurrence_NN of_IN prostate_NN cancer_NN ._.
        Further_RB genes_NNS have_VBP been_VBN described_VBN with_IN other_JJ unexpected_JJ roles_NNS in_IN the_DT tumourigenic_JJ process_NN ._.
        There_EX is_VBZ a_DT long-standing_JJ debate_NN in_IN the_DT literature_NN about_IN the_DT number_NN and_CC role_NN of_IN mutations_NNS in_IN
        a_DT tumour_NN ,_, and_CC without_IN going_VBG into_IN the_DT details_NNS ,_, it_PRP is_VBZ clear_JJ that_IN haploinsufficient_NN mechanisms_NNS
        for_IN tumour_NN suppressor_NN genes_NNS will_MD greatly_RB influence_VB the_DT statistics_NNS on_IN which_WDT these_DT
        discussions_NNS are_VBP based_VBN ._. At_IN a_DT time_NN when_WRB microarray_NN analysis_NN has_VBZ become_VBN a_DT standard_JJ experiment_NN
        and_CC the_DT many_JJ thousands_NNS of_IN changes_NNS in_IN tumour_NN cells_NNS are_VBP analysed_JJ across_IN the_DT whole_JJ genome_NN ,_, it_PRP
        is_VBZ important_JJ to_TO keep_VB in_IN mind_NN that_IN the_DT correct_JJ interpretation_NN of_IN this_DT wealth_NN of_IN information_NN
        might_MD be_VB more_RBR complicated_JJ than_IN the_DT widely_RB accepted_VBN models_NNS would_MD have_VB us_PRP believe_VB ._.
      
      
        
      
    
  
